Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Tierney JF, Vogle A, Poirier J, Min IM, Finnerty B, Zarnegar R, et al. Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study. Surgery. 2019;165(1):196-201.

Liu D, Fiel RH, Cheng LS, Ogami T, Wang L, Singh V, et al. Notes from the Field: First Reported Case of Shewanella haliotis in the Region of the Americas - New York, December 2018. MMWR Morb Mortal Wkly Rep. 2019;68(50):1168-1169.

Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, et al. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(22):6839-6851.

Chidambaram S, Pannullo SC, Roytman M, Pisapia DJ, Liechty B, Magge RS, et al. Dynamic contrast-enhanced magnetic resonance imaging perfusion characteristics in meningiomas treated with resection and adjuvant radiosurgery. Neurosurg Focus. 2019;46(6):E10.

Vlismas PP, Heymann JJ, Marboe CC, Jorde UP, Sims DB. Quadravalvular Noninfectious Endocarditis. JACC Case Rep. 2019;1(3):350-354.

McIntire PJ, Snow JT, Elsoukkary SS, Soong L, Sweeney J, Robinson BD, et al. Digital image analysis supports a nuclear-to-cytoplasmic ratio cutoff value below 0.7 for positive for high-grade urothelial carcinoma and suspicious for high-grade urothelial carcinoma in urine cytology specimens. Cancer Cytopathol. 2019;127(2):120-124.

Droesch C, Magro C. A comedonal variant of chronic cutaneous lupus erythematosus: Case report and literature review. JAAD Case Rep. 2019;5(9):801-805.

Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan WC, Dodero A, et al. Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. Am J Hematol. 2019;94(6):628-634.

Hamid AA, Gray KP, Shaw G, Macconaill LE, Evan C, Bernard B, et al. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019;76(1):89-97.

Bartlett NL, Wilson WH, Jung S-, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799.